Trial Profile
Remicade [infliximab] Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.; Organon; Schering-Plough
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Oct 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 26 Aug 2008 New trial record.